Immunome (NASDAQ:IMNM) and Bicara Therapeutics (NASDAQ:BCAX) Critical Analysis

Bicara Therapeutics (NASDAQ:BCAX) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Bicara Therapeutics and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	N/A	N/A
Immunome	-3,014.59%	-48.63%	-41.62%

Insider & Institutional Ownership

44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bicara Therapeutics and Immunome”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
Immunome	$10.13 million	57.80	-$106.81 million	($8.11)	-1.16

Bicara Therapeutics has higher earnings, but lower revenue than Immunome.

Analyst Ratings

This is a summary of current ratings and target prices for Bicara Therapeutics and Immunome, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	0	0	6	1	3.14
Immunome	0	0	7	0	3.00

Bicara Therapeutics presently has a consensus price target of $43.00, indicating a potential upside of 234.89%. Immunome has a consensus price target of $28.83, indicating a potential upside of 207.39%. Given Bicara Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Bicara Therapeutics is more favorable than Immunome.

Summary

Bicara Therapeutics beats Immunome on 6 of the 10 factors compared between the two stocks.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.